Building better base editors

VIB scientists develop ITER, a sensitive, versatile, and high-throughput method to test and quantify gene editing in plant cells

CRISPR gene editing is a powerful biotechnology tool that allows scientists to alter specific DNA sequences. New research is constantly refining and improving CRISPR technology. Researchers from the team of Prof. Thomas Jacobs (VIB-UGent Center for Plant Systems Biology), together with BASF Innovation Center Gent and colleagues from the VIB screening Core and VIB Flow Core, now report an important advance in CRISPR base editing technology. Their work was funded by VLAIO and appears in Genome Biology.

The scientific world was rocked in 2012 by the development of CRISPR gene-editing tools using the DNA-cutting protein Cas9, an advance that received a Nobel Prize in 2020. CRISPR technology now has applications all across the biological sciences, from improving the crops we rely on to use in medicine treating sickle cell disease, cancer, and other diseases.

The original CRISPR technology from a decade ago did have some limitations. For instance, it was not very easy to control the types of DNA changes that were being made. The development of ‘base editors’ in 2016 changed all of that. CRISPR base editors are particularly powerful as they can replace one specific DNA base (a DNA ‘letter’) with another allowing for very precise changes in the DNA sequence.

Prof. Thomas Jacobs: “When we started the project, there were a few problems with the existing CRISPR base editors. The first was that they didn’t work that well. Only a quarter of our targets were edited. The second was that, by then, there was a large number of different CRISPR parts. Using our existing methods to test and evaluate all of the different combinations to find the best one would take too much time. So, we developed ITER.”

ITER, or Iterative Testing of Editing Reagents, is a sensitive, versatile, and high-throughput method to test and quantify gene editing in plant cells. It is a way to simultaneously test many potential base editors in many cells. A fully automated imaging and analysis pipeline allows the researchers to rapidly test the different editors and design the next experiment. Each iteration only takes a few weeks to complete, so optimization proceeds quickly.

In the first use of ITER, the researchers identified a variant of Cas12a (an alternative DNA-cutting protein) that efficiently performs base editing in wheat and maize cells. The first Cas12a base editors only edited about one in 200 cells. But by rapidly performing multiple rounds of testing with ITER, they were able to increase editing efficiency to about 40%.

Dr. Christophe Gaillochet, first author of the study: “Especially in plants, this improvement is a great step forward, not only because previous base editors with Cas12a didn’t perform well, but also because it gives us a much better tool for plant breeding to make our crops more resilient to challenging environments caused by climate change.”

The team is now using ITER to optimize different types of genome editing tools in a variety of plant species.


Publication

Systematic optimization of Cas12a base editors in wheat and maize using the ITER platform. Gaillochet et al. Genome Biology, 2023.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Rainbow Crops raises €9.7M seed round to scale AI-driven multiplex gene editing for next-generation crops
The round was led by Italian venture capital company LIFTT, together with its vehicle LIFTT EuroInvest
press.vib.be
Website preview
Researchers identify a key biological tipping point in Alzheimer’s disease
Leuven, 4 June 2026 – Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer’s disease pathology leads to dementia. Studying brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians, the team identified distinct cellular programs and immune-cell states associated with disease progression and resilience. Their findings, published in Nature Medicine, suggest that changes in microglia—the brain’s resident immune cells—could represent an important target for future Alzheimer’s therapies.
press.vib.be
Website preview
Prof. Diether Lambrechts (KU Leuven/VIB) receives the Francqui-Collen Prize 2026
Brussels, June 2, 2026 – Prof. Dr. Diether Lambrechts (KU Leuven/VIB) and Prof. Dr. Patrice Cani (UCLouvain) are the laureates of the Francqui-Collen Prize 2026, one of the highest scientific distinctions in Belgium. Today, they receive the award from the hands of King Philippe. Prof. Lambrechts is being honored for his groundbreaking genetic research into cancer treatments, while Prof. Cani is recognized for his discoveries regarding the impact of gut bacteria on lifestyle-related diseases.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be